Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)
ANNÉE
2023
AUTEURS
Samalin E, Senellart H, Evesque L, Bouché O, Khemissa F, De La Fouchardiere C, Lopez A, Dermeche S, Botsen D, Tougeron D,Zaanan A,BEN Abdelghani M,Guardiola E,Dubreuil O,Le Brun Ly V,Hennequin A,Carvalho N, Castan F, Anthony Turpin A
CONGRÈS/REVUE
ASCO GI
LIEN PUBLICATIONS ASSOCIÉES